Literature DB >> 20520605

Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation.

R de Greef1, A S Zandvliet, A F J de Haan, P C Ijzerman-Boon, M Marintcheva-Petrova, B M J L Mannaerts.   

Abstract

In controlled ovarian stimulation (COS), a single subcutaneous dose of corifollitropin alfa is used to initiate and sustain multifollicular growth for 7 days. The objective of this study was to determine the optimal dose of corifollitropin alfa. A pharmacokinetic model was developed to describe the time profile of corifollitropin alfa concentrations. Multiple parameters reflecting ovarian response were included in a pharmacokinetic-pharmacodynamic (PK-PD) model framework. An early decline in serum inhibin B was shown to be a sensitive marker for COS failure. Simulations were performed to select the lowest corifollitropin alfa dose that would result in a minimal cancellation rate: 100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg. With these doses, the predicted mean number of oocytes per started COS cycle was similar in the two groups, i.e., 12.1 and 13.2, respectively. The selected doses were tested in prospective clinical trials and were proven to be adequate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520605     DOI: 10.1038/clpt.2010.54

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

2.  Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation.

Authors:  Anthe S Zandvliet; Marita Prohn; Rik de Greef; Frank van Aarle; Christine McCrary Sisk; Barbara J Stegmann
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

Review 3.  Gonadotropin stimulation: past, present and future.

Authors:  Bruno Lunenfeld
Journal:  Reprod Med Biol       Date:  2011-07-13

4.  The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.

Authors:  Ayse Seyhan; Baris Ata
Journal:  Int J Womens Health       Date:  2011-08-08

5.  Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.

Authors:  Robert J Norman; Fernando Zegers-Hochschild; Bruno S Salle; Jolanda Elbers; Esther Heijnen; Maya Marintcheva-Petrova; Bernadette Mannaerts
Journal:  Hum Reprod       Date:  2011-05-27       Impact factor: 6.918

6.  Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.

Authors:  Stefania Fensore; Marco Di Marzio; Gian Mario Tiboni
Journal:  J Ovarian Res       Date:  2015-06-03       Impact factor: 4.234

7.  A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.

Authors:  Huai-Ling Wang; Hsing-Hua Lai; Tzu-Hsuan Chuang; Yu-Wei Shih; Shih-Chieh Huang; Meng-Ju Lee; Shee-Uan Chen
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

8.  An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders.

Authors:  Chen-Yu Huang; Guan-Yeu Chen; Miawh-Lirng Shieh; Hsin-Yang Li
Journal:  Reprod Biol Endocrinol       Date:  2018-03-05       Impact factor: 5.211

9.  Association of progesterone production with serum anti-Müllerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa.

Authors:  Tsung-Hsien Lee; Shu-Ling Tzeng; Chun-I Lee; Hsiu-Hui Chen; Chun-Chia Huang; Shee-Uan Chen; Maw-Sheng Lee
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

10.  Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses.

Authors:  Trine Høyer Rose; Daniel Röshammar; Lars Erichsen; Lars Grundemar; Johnny T Ottesen
Journal:  Drugs R D       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.